Expression pattern alterations of syndecans and glypican-1 in normal and pathological trophoblast.
Syndecans (syn-1, -2, -3, -4) and glypican-1 are proteoglycans expressed during development in association with changes in tissue organization and differentiation. They participate in the modulation of growth factor actions and in cell-cell and cell-matrix adhesion. The expression of syn-1, -2, -3, -4, and glypican-1 has been studied in normal human placenta and in gestational trophoblastic disease such as hydatidiform mole, invasive mole, and choriocarcinoma, using immunohistochemistry and western blots. Syndecan-3 was not expressed in normal or pathological tissues. During normal gestation, the other proteoglycans showed a specific staining pattern, which for some was modified during pregnancy. For instance, syn-1 was only expressed in syncytiotrophoblast; syn-4 was mainly localized in the villous and extravillous cytotrophoblast in the first trimester, whereas at term it was expressed in the syncytiotrophoblast. The most striking results are the altered expression patterns of syndecans and glypican-1 in pathological tissues. These proteoglycans showed a progressive decrease of immunostaining related to the increase of severity of trophoblastic disease, in particular in invasive mole and choriocarcinoma. In addition, dysregulation in the localization of the expression patterns was observed for syn-2 and -4. Because changes in syndecan expression enable cells to become more or less responsive to their micro-environment, the down-regulation and/or dysregulation of syndecans in relation to the degree of severity of trophoblastic diseases provides new insights into the progression of these pathologies.
Crescimanno
C
C
Institute of Anatomy and Histology, University of Verona, Italy.
Marzioni
D
D
Paradinas
F J
FJ
Schrurs
B
B
Mühlhauser
J
J
Todros
T
T
Newlands
E
E
David
G
G
Castellucci
M
M
D015153:Blotting, Western; D002822:Choriocarcinoma / Q000378:metabolism / Q000473:pathology; D005260:Female; D006493:Heparin / Q000031:analogs & derivatives / Q000032:analysis; D006801:Humans; D006828:Hydatidiform Mole / Q000378:metabolism* / Q000473:pathology; D002820:Hydatidiform Mole, Invasive / Q000378:metabolism / Q000473:pathology; D007150:Immunohistochemistry; D008562:Membrane Glycoproteins / Q000032:analysis; D009363:Neoplasm Proteins / Q000032:analysis; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011263:Pregnancy Trimester, Third; D011509:Proteoglycans / Q000032:analysis*; D053671:Syndecan-4; D053667:Syndecans; D014327:Trophoblasts / Q000378:metabolism* / Q000473:pathology; D014594:Uterine Neoplasms / Q000378:metabolism / Q000473:pathology
D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; D011509:Proteoglycans; C508304:SDC4 protein, human; D053671:Syndecan-4; D053667:Syndecans; C036090:heparin proteoglycan; D006493:Heparin